dabrafenib
NICE Recommends Novartis' BRAF, MEK Inhibitor Combo for BRAF-Mutant Pediatric Glioma
The UK's National Institute for Health and Care Excellence recommended the combination treatment for pediatric patients with BRAF V600E-mutant low- or high-grade glioma.
Novartis Focused on Radiopharmaceutical Expansion After Pluvicto, Lutathera Sales Both Grow in Q3
Premium
The Swiss drugmaker also reported revenue increases across other precision oncology products including its breast cancer drug Kisqali.
NICE Recommends Novartis' Tafinlar-Mekinist as Frontline Treatment for BRAF-Mutant NSCLC
The agency estimated that the drug combination's cost-effectiveness falls within what it considers an acceptable use of the NHS's resources.
The Swiss firm reported solid sales growth across its oncology portfolio during the first quarter of 2023 as overall sales increased 3 percent.
Adults with BRAF-mutated glioma have higher-grade tumors and decreased survival compared to children but can still benefit from targeted therapies.